Company:  ARRAY BIOPHARMA INC (ARRY)
Form Type:  10-Q
Filing Date:  2/6/2013 
CIK:  0001100412 
Address:  3200 WALNUT STREET 
City, State, Zip:  BOULDER, Colorado 80301 
Telephone:  (303) 381-6600 
Fiscal Year:  06/30 
Last Trade
Last Trade: 
$4.09  
Change: 
0.29 (7.63%)  
Trade Time: 
04:00 PM EST  
Market Cap: 
$513.12M
Description of Business
Array BioPharma Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer. Array is evolving into a late-stage development company and is generating data to support our upcoming Phase 3 / pivotal trial decisions. Novartis International Pharmaceutical Ltd. began a Phase 3 trial evaluating Array-invented MEK162 in NRAS-mutant melanoma in July 2013 and expects to begin a Phase 3 trial in BRAF-mutant melanoma in 2013. In addition, Array began a Phase 3 trial evaluating MEK162 in low-grade serous ovarian cancer under the License Agreement with Novartis in June 2013. AstraZeneca, PLC began a pivotal trial with Array-invented selumetinib in thyroid cancer in May 2013 and expects to begin a Phase 3 trial in non-small cell lung cancer in 2013. Three other Array-invented drugs are also approaching Phase 3 or pivotal trial decisions which are expected by the end of 2013.
Register for EDGAR Pro and access this filing in:     
  FORM 10-Q
    PART I. FINANCIAL INFORMATION
      ITEM 1. CONDENSED FINANCIAL STATEMENTS
        INCOME STATEMENT
        STOCKHOLDERS EQUITY
        CASH FLOW
        NOTE 1 - OVERVIEW AND BASIS OF PRESENTATION
      ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL ...
      ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT ...
      ITEM 4. CONTROLS AND PROCEDURES
    PART II. OTHER INFORMATION
      ITEM 1. LEGAL PROCEEDINGS
      ITEM 1A. RISK FACTORS
      ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF ...
      ITEM 3. DEFAULTS UPON SENIOR SECURITIES
      ITEM 4. MINE SAFETY DISCLOSURES
      ITEM 5. OTHER INFORMATION
      ITEM 6. EXHIBITS
    SIGNATURES
  EXHIBIT 10.2
  EXHIBIT 10.3
  EXHIBIT 10.4
  EXHIBIT 31.1
    CERTIFICATION OF CHIEF EXECUTIVE OFFICER
  EXHIBIT 31.2
    CERTIFICATION OF CHIEF FINANCIAL OFFICER
  EXHIBIT 32.1
    CERTIFICATIONS OF CHIEF EXECUTIVE OFFICER AND CHIEF ...
BROKERAGE PARTNERS